COMPASS THERAPEUTICS (CMPX)
Health Care · Clinical-stage immuno-oncology biopharmaceuticals · NASDAQ
Compass Therapeutics is a clinical-stage oncology company developing a pipeline of bispecific and agonistic antibodies designed to treat solid tumors by targeting angiogenesis and immune system pathways.
What COMPASS THERAPEUTICS does
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human cancers. The company focuses on targeting relationships between angiogenesis, the immune system, and tumor growth through a pipeline of bispecific and agonistic antibodies designed to modulate the microvasculature, induce potent immune responses, and relieve immunosuppressive mechanisms in the tumor microenvironment. The company currently has four clinical product candidates in development, with its lead program (tovecimig/CTX-009) targeting DLL4 and VEGF-A in biliary tract cancer and other solid tumors.
Themes: oncology, bispecific antibodies, angiogenesis inhibitors, immune-oncology, checkpoint inhibitors, solid tumors
Fundamentals
- Price$2.40 as of 2026-08-21 close
- Market cap$432M as of 2026-08-21
- 1-year return-14.3% 2025-08-21 close $2.80 → 2026-08-21 close $2.40
- P/En/a negative earnings
- Net margin-5808.8% as of 2026-08-24
- ROE-29.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.88 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CMPX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How COMPASS THERAPEUTICS looks technically
COMPASS THERAPEUTICS (CMPX) is trading 41.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 70 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 65.1% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 41.2% below its 200-day average, the long-term trend line — a long-term downtrend | -41.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.14 | $2.14 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.08 | $4.08 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 25 calendar days ago — the swings before that are what the structure reading is measured on | 25 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 70 trading days ago — a "death cross", a bearish long-term signal | 70 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 60.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.85 to $2.52) — its "stochastic" reading is 82 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 82.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.88 | $6.88 |
|---|---|---|
| From the 52-week high | it is 65.1% below its 52-week high (its highest price of the past year) | -65.1% |
| Above the 52-week low | it is 49.1% above its 52-week low (its lowest price of the past year) | +49.1% |
| Below the 52-week high | it is 65.1% below its highest point of the past year | 65.1% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $11.00 (set on 2021-04-16) | $11.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.67 to $6.69), and it has recovered only a small part of its fall from last year’s high — 15% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.77 to $4.93. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 14.5% |
| From the all-time high | it is 78.2% below its all-time high | -78.2% |
| Nearest price level | it is trading 2.2% below a resistance level at $2.45 — a price it turned at twice since 2025-04-02, most recently on 2026-05-29. Since 2024-08-21 it has 7 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.2% |
| All-time low | its lowest closing price on record is $0.765 (set on 2024-07-05) | $0.765 |
| Above the all-time low | it is 213.7% above its all-time low | +213.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1379 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1379 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.77 and $2.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.77 – $2.15 – $2.53 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 12.2 daily ranges below its 200-day average price (41.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.69× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.3% |
|---|---|---|
| Open gap | it gapped 2.4% below the previous close 1 session ago and has not traded back through the level it left behind at 2.48 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.4% |
| Gap filled | a 2.2% gap down opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.0 percentage points (the stock gained 14.3% while the market gained 2.3%) | +12.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 21.3 percentage points (the stock gained 24.4% while the market gained 3.1%) | +21.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 72.2 percentage points (the stock lost 61.1% while the market gained 11.1%) | -72.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 34.8 percentage points (the stock lost 14.3% while the market gained 20.5%) | -34.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 10% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.5% of the share price. | +10.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.91 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -17.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.26 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +6.1% |
Price levels it has turned at before
CMPX last closed at $2.40 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.45 | Resistance | 2.2% above the last close | turned there twice · 2025-04-02 to 2026-05-29 |
| $2.15 | Support | 10.2% below the last close | turned there twice · 2025-06-17 to 2026-06-17 |
| $2.66 | Resistance | 10.8% above the last close | turned there twice · 2025-08-11 to 2025-08-19 |
| $2.00 | Support | 16.5% below the last close | turned there three times · 2024-09-30 to 2026-05-14 |
| $1.87 | Support | 22.0% below the last close | turned there twice · 2024-09-16 to 2026-06-11 |
| $3.29 | Resistance | 37.3% above the last close | turned there twice · 2025-09-22 to 2025-10-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · lagging the market · Printed a doji candle · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$8.92 range $5.00 – $24.00; median $7.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CMPX
- Consensus EPS estimate-$0.1255 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage development risk: all four product candidates remain in clinical trials with uncertain outcomes and regulatory approval timelines, and failure in Phase 2/3 trials could derail commercialization plans.","Limited cash runway: the company had ~$55M in cash as of March 31, 2026, with quarterly operating burn of ~$20M, limiting ability to fund clinical programs without additional financing.","Competitive landscape: the immuno-oncology and cancer therapy space is crowded with established competitors (Merck, Roche, Bristol Myers Squibb) with approved checkpoint inhibitors and combination therapies, creating significant commercialization risk."]
What changed in the latest 10-Q
AI-assisted comparison of CMPX's 10-Q filed 2026-05-05 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) adds detailed April 2026 tovecimig Phase 2/3 study results including ORR (17.1% vs 5.3%), PFS (4.7 vs 2.6 months), OS data, crossover analyses, and safety findings
- Newer filing adds statement that tovecimig received FDA Orphan Drug Designation in April 2026 for BTC with associated benefits
- Newer filing adds intent to meet with FDA to discuss data in advance of planned BLA submission
- Newer filing reports net losses of $18.3 million and $16.6 million for three months ended March 31, 2026 and 2025
- Newer filing reports accumulated deficit of $449.5 million on March 31, 2026
- Newer filing reports $195 million in cash, cash equivalents and marketable securities as of March 31, 2026
- Removed:
- Older filing (2025-11-05) describes pipeline as 'three clinical product candidates and one candidate in investigational new drug application (IND) enabling studies'; newer filing describes pipeline as 'four clinical product candidates'
- Older filing states CTX-10726 is 'in the process of IND enabling studies'; newer filing lists it as a clinical product candidate
- Older filing notes tovecimig Phase 2/3 study results 'expected late Q1 2026' (forward-looking); newer filing provides actual results
- Older filing discusses CTX-8371 Phase 1 dose-escalation study enrollment and expectations for full topline data presentation in first half of 2026
- Older filing reports net losses of $14.3 million and $10.5 million for three months ended September 30, 2025 and 2024, and nine-month comparisons
- Older filing reports accumulated deficit of $415.5 million on September 30, 2025
- Older filing reports $220 million in cash, cash equivalents and marketable securities as of September 30, 2025
- Older filing includes statement about cash resources enabling operations into 2028
- Reworded:
- Newer filing references Annual Report 'for the fiscal year ended December 31, 2025' vs older filing referencing 'December 31, 2024'
- Newer filing describes Overview as 'to treat multiple human diseases' vs older filing saying 'antibody-based therapeutics' without specifying multiple diseases
- Newer filing says pipeline is 'designed to target multiple components required' vs older filing saying 'designed to target multiple critical biological pathways required'
- Newer filing says 'Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our therapies' vs older filing saying 'our treatments'
- Notes:
- The older filing covers nine months ended September 30, 2025 while the newer filing covers three months ended March 31, 2026, making period-to-period comparisons of financial metrics not directly comparable
- The newer filing text appears truncated at the end ('We expect that such cash re'), so full content comparison may be incomplete for later sections
Risk Factors
- Added:
- Newer filing (2026-05-05) includes financial statements as of March 31, 2026 and December 31, 2025, whereas older filing (2025-11-05) covered September 30, 2025 and December 31, 2024
- Newer filing reports three months ended March 31, 2026 operations; older filing reported three months and nine months ended September 30, 2025
- Newer filing shows cash and cash equivalents of $55,168 thousand as of March 31, 2026; older filing showed $46,212 thousand as of September 30, 2025
- Newer filing displays accumulated other comprehensive loss of $(159) thousand; older filing showed accumulated other comprehensive income of $274 thousand
- Newer filing reports net loss of $(18,317) thousand for three months ended March 31, 2026; older filing reported $(14,259) thousand for three months ended September 30, 2025
- Newer filing shows common stock issued upon exercise of options (1,563 shares); older filing did not separately disclose option exercises in the three-month periods shown
- Newer filing reports unrealized loss on marketable securities of $(439) thousand; older filing reported unrealized gain of $66 thousand for the three months ended September 30, 2025
- Removed:
- Older filing (2025-11-05) included licensing revenue of $850 thousand for the nine months ended September 30, 2024; newer filing (2026-05-05) does not report licensing revenue
- Older filing included comparative nine-month period data for 2025 and 2024; newer filing only provides three-month comparative data
- Older filing detailed common stock and warrants issuance in September 2025; newer filing does not reflect such issuance activity in its reporting period
- Reworded:
- Accumulated other comprehensive income/loss changed from positive $274 thousand (older, September 30, 2025) to negative $(159) thousand (newer, March 31, 2026)
- Balance sheet line items shifted from September 30, 2025/December 31, 2024 comparison to March 31, 2026/December 31, 2025 comparison
- Operating lease obligations current portion increased from $633 thousand to $1,373 thousand between the two filing periods
- Notes:
- The two filings cover different fiscal periods (March 31, 2026 versus September 30, 2025), making direct operational comparisons limited to the three-month periods that do overlap
- Financial data reflects the passage of time and different operational phases rather than accounting policy or presentation changes
- The Nature of Business section text in newer filing appears truncated in the provided excerpt, limiting full comparison of that disclosure
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days2 buys ($75600) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-04-29. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CMPX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CMPX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 18,893,887
- Reported value $99,948,662
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CMPX had 39,874,250 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CMPX had 22.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.62 days to cover at the same settlement.
- Reported short interest (shares) 39,874,250
- Short interest (% of shares outstanding) 22.1%
- Prior settlement (shares) 39,298,468
- Reported change 1.47%
- Days to cover (reported) 17.62
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- Regeneron Pharmaceuticals (REGN)
- Moderna (MRNA)
- Alnylam Pharmaceuticals (ALNY)
- Surface Oncology
- Jounce Therapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CMPX vs…
COMPASS THERAPEUTICS is found in…
CMPX ranks in…
Frequently asked questions
What does COMPASS THERAPEUTICS (CMPX) do?
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human cancers. The company focuses on targeting relationships between angiogenesis, the immune system, and tumor growth through a pipeline of bispecific and agonistic antibodies designed to modulate the microvasculature, induce potent immune responses, and relieve immunosuppressive mechanisms in the tumor microenvironment.
What sector is COMPASS THERAPEUTICS (CMPX) in?
COMPASS THERAPEUTICS (CMPX) is classified in the Health Care sector. Its industry is Clinical-stage immuno-oncology biopharmaceuticals. It trades on NASDAQ.
Who are COMPASS THERAPEUTICS's (CMPX) competitors?
Notable peers of COMPASS THERAPEUTICS (CMPX) include Merck, Bristol Myers Squibb, Regeneron Pharmaceuticals, Moderna and Alnylam Pharmaceuticals. This peer set is informational only — not financial advice.
Is COMPASS THERAPEUTICS (CMPX) overbought or oversold right now?
COMPASS THERAPEUTICS (CMPX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CMPX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.